Fig. 1From: CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancerClinical outcome in patients treated with induction chemotherapy. PFS (median 20 months a) and OS (median 31 months b) in all patients treated with first line TPF induction chemotherapyBack to article page